Researchers at the University of Southampton have introduced a novel strategy aimed at enhancing the immune system’s ability to combat cancer. This research, published in the journal Nature Communications, focuses on engineered antibodies designed to more effectively activate T cells, which play a crucial role in targeting and destroying cancer cells.
The new antibodies function by simultaneously binding multiple immune cell receptors, thereby amplifying the signals that prompt T cells to initiate an immune response against tumors. The study specifically investigated the CD27 receptor, which requires a corresponding ligand to activate T cells. While the body produces this ligand during infections, cancer cells typically do not, resulting in a weak activation signal that hampers T cell effectiveness.
Traditional antibodies, commonly used in cancer therapies, possess a Y-shaped structure with two arms, limiting their ability to engage multiple receptors simultaneously. This structural limitation can lead to insufficient activation of T cells in some cancer types, where a combination of signals is necessary for a robust immune response.
In contrast, the antibodies developed in this study feature four binding arms, enabling them to connect with more receptors at once. This design not only enhances the clustering of CD27 receptors but also recruits additional immune cells to strengthen the activation signal, mimicking the natural mechanism of CD27 activation in the body.
Preliminary laboratory tests on mice and human immune cells indicate that these new antibodies significantly outperform standard Y-shaped antibodies in activating CD8+ T cells, often referred to as the immune system’s “special forces.” The findings suggest that this innovative approach could pave the way for more effective immunotherapies that fully leverage the immune system’s capabilities in fighting cancer. The research was supported by Cancer Research UK and underscores the Centre for Cancer Immunology’s commitment to advancing cancer treatment methodologies.
